$8 Billion Risperdal Judgment Reduced to $6.8 Million
The judge presiding over a case which saw Johnson & Johnson hit with an $8bn jury verdict has reduced the amount the company has to pay in damages to $6.8m.
Last October, J&J was ordered to pay $8bn in damages to a US man who claims he was not warned that taking the company’s antipsychotic Risperdal could lead to breast growth.
A jury in Philadelphia agreed with the allegation that J&J’s Janssen unit had downplayed the risk that use of Risperdal (risperidone) in male children can cause enlarged breasts, a condition known as gynaecomastia.